CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75.2% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

VirBiotechnology live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

VirBiotechnology news

Emma Rose 2025 Jul 03, 08:35

US Economy on Stagflation Watch: Apollo Global Management's Outlook

Ava Grace 2025 Jul 03, 08:35

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

Sophia Claire 2025 Jul 03, 07:35

S&P 500 Earnings Season to Test Rally Amidst Dim Outlook

Sophia Claire 2025 Jul 03, 07:35

AI Podcast: Stock Market Melt-Up Potential? Examining the Bull Run

Noah Lee 2025 Jul 03, 07:35

AI Podcast: Does the Gold-Platinum Ratio Signal Stock Market Risk?

Latest news

Show more
Noah Lee 2025 Jul 15, 02:20

Bitcoin Breaks Consolidation, Surges Above $120K Amid Regulatory Optimism

Emma Rose 2025 Jul 15, 01:20

Kevin Hassett Emerges as Potential Fed Chair Under Trump: An Analysis

liam james 2025 Jul 15, 01:20

US-EU Trade Tensions Escalate: Tariff Threats Loom Large

Frances Wang 2025 Jul 14, 16:00

Stock Movers Today: Autodesk, PayPal, Rivian, Nebius, Waters

Stocks
Sophia Claire 2025 Jul 14, 13:20

Trump Admin Leverages Fed Renovation for Powell Ouster Amid Rate Dispute

Emma Rose 2025 Jul 14, 13:20

Pound Sterling Outlook: Interest Rates and Economic Indicators in Focus

Sophia Claire 2025 Jul 14, 09:20

Trump's Tariff Threat Looms: Will It Trigger EU Recession and Force ECB Rate Cuts?

Noah Lee 2025 Jul 14, 08:23

Federal Reserve Renovation Project: Defending Costs and Features

Info

Spread

0.05

Spread (%)

0.9124 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Tuesday

13:31 - 19:59

Monday

13:31-19:59

Wednesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

781044736

Shares Outstanding

138238000

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-4.23

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments

Latest Education Articles

Show more
Ghko B 2025 Jul 14, 16:00

NBIS Stock Jumped over 17%: What Happened to Nebius Group?

Shares Stocks
Markets.com Support Team 2025 Jul 13, 21:00

Crypto 2025: Exploring the Trends and How It’s Shaping Trading Behavior

Crypto
Ghko B 2025 Jul 13, 16:00

BA Stock Is Rising Now: Is Boeing Company Stock (BA) a Buy Now?

Stocks
Trustpilot